Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 25,184 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PRE Clear all

Conditions: MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions: MR exam, US exam, Blood draw, Physical measurements, Questionnaires; Diagnostic Test · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 9 Years to 18 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Prostate Cancer
Interventions: 89ZR-DF-IAB2M, 68Ga-PSMA-HBED-CC; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C Virus (HCV)
Interventions: Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 15
States / cities: San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 11 more

Conditions: ENT Patients Scheduled for Surgery
Interventions: Not listed
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Redlands, California

Conditions: Chronic Pain, Back Pain
Interventions: Epidural injection, Epidural steroid injection as determined by routine care provider; Procedure · Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV)
Interventions: Acasunlimab, Pembrolizumab; Biological
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: IGT - Impaired Glucose Tolerance, T2D
Interventions: Oral Glucose Tolerance Test, Hyperglycemic Clamp, Isoglycemic Intravenous Glucose Test, Hyperinsulinemic Euglycemic Clamp and 2H20; Diagnostic Test
Lead sponsor: Yale University; Other
Eligibility: 12 Years to 18 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour, Head and Neck Cancer, Liver Cancer, Melanoma, Mouth Cancer, Nasopharangeal Cancer, Neuroendocrine, Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcoma, Small Cell Lung Cancer, Testicular Cancer, Throat Cancer, Thyroid Cancer, Urethral Cancer, Vaginal Cancer, Vulvar Cancer
Interventions: Trastuzumab deruxtecan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 18
States / cities: Birmingham, Alabama • Bullhead City, Arizona • Casa Grande, Arizona + 15 more

Conditions: Melanoma
Interventions: Entinostat, Pembrolizumab; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Eating Disorders, Binge Eating, Purging (Eating Disorders)
Interventions: Naltrexone; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 13 Years to 21 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Dysmenorrhea, Dysmenorrhea Primary, Visceral Pain, Menstrual Pain
Interventions: Visceral Pain Stimulus; Diagnostic Test
Lead sponsor: Azusa Pacific University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Azusa, California

Conditions: Anemia, Sickle Cell
Interventions: Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Duarte, California

Conditions: Anorexia Nervosa
Interventions: Positive Affect Treatment for Anorexia Nervosa (PAT-AN):, Psychoeducational and Behavioral Therapy (PBT); Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Clinical Outcomes
Interventions: Unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system.; Procedure
Lead sponsor: Foundation for Orthopaedic Research and Education; Other
Eligibility: 21 Years to 100 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Pre-Diabetes, Diabetes, Cardiovascular Risks
Interventions: Not listed
Lead sponsor: Mike O'Callaghan Military Hospital; Federal
Eligibility: 18 Years and older
Enrollment: 535 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Pregnancy Prevention, Life Skill Development
Interventions: Healthy Adolescent Transitions (HAT) program; Behavioral
Lead sponsor: Jack Stevens; Other
Eligibility: 14 Years to 19 Years · Female only
Enrollment: 331 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Head and Neck Cancer, Pain, Postoperative
Interventions: Pregabalin 150mg, Placebo; Drug · Other
Lead sponsor: Augusta University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
Interventions: Valbenazine; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 19
States / cities: Bryant, Arkansas • Chino, California • Fresno, California + 16 more

Conditions: Obesity
Interventions: Ensure and Water; Other
Lead sponsor: Drexel University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Untreated Childhood Brain Stem Glioma
Interventions: motexafin gadolinium, radiation therapy, pharmacological study; Drug · Radiation · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Arcadia, California

Conditions: Sickle Cell Disease, Vaso-Occlusive Crisis
Interventions: Ketamine; Drug
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 10 Years to 25 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Oakland, California

Conditions: Kidney Transplant
Interventions: Infliximab, Methylprednisolone, Mycophenolate Mofetil, Tacrolimus, Thymoglobulin®, Acetaminophen, Loratadine, Placebo for Infliximab, Prednisone, Diphenhydramine; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more

Conditions: HIV Infections
Interventions: Atazanavir, Lopinavir/Ritonavir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 38
States / cities: Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 30 more

Conditions: Osteoarthritis of the Knee
Interventions: Instrument; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Quantitative Ultrasound to Assess Steatotic Liver Disease in Children

PSMA Imaging of Localized Prostate Cancer

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

Comparison of Telemedicine Evaluation to Standard Evaluation Methods for Pre-Anesthesia Consultation

Tracking Outcomes in Pain Patients Using Fitness Devices

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes

DESTINY-PANTUMOUR04

An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma

Naltrexone Neuroimaging

A Research Study Exploring How Musculoskeletal Function and the Autonomic Nervous System Relate to Visceral Pain in Women With and Without Dysmenorrhea (Painful Periods).

CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease

Neuroscience-informed Treatment to Remotely Target Reward Mechanisms in Post-acute Anorexia Nervosa

MAKO-Uni-Knee Arthroplasty Clinical Outcomes and Function

A1c FIT TEST: An Epidemiological Study Correlating Hemoglobin A1c With Results of the Air Force Physical FITness TEST.

Healthy Adolescent Transitions (HAT)

Pre-Operative Pregabalin for Post-Operative Pain in Head and Neck Cancer Surgery

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

A Translational Understanding of Obesity-Related Phenotypes Using Brain Imaging and Manipulation

Motexafin Gadolinium Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma

Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis

Effects of Inhibiting Early Inflammation in Kidney Transplant Patients

Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)

A Randomized Prospective Trial of Total Knee Arthroplasty Options Comparing Standard Knee Cutting Guides and MRI Generated Patient Specific Custom Cutting Guides